This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

British Pharmacological Society appoints new President-elect

Published: 03 Feb 2022 in Society news



The British Pharmacological Society is pleased to announce the appointment of Professor Sir Mark Caulfield as its new President-elect.

Sir Mark is Professor of Clinical Pharmacology at Queen Mary University of London and Vice Principal for Health for Queen Mary’s Faculty of Medicine and Dentistry. From 2013 to July last year, he was Chief Scientist for Genomics England, where he led the successful strategic delivery of the 100,000 Genomes Project, for which he was knighted in 2019.

The Society welcomes Sir Mark to its governing body at a time when pharmacology’s profile among our communities is higher than ever before, following the incredible and life-saving work of pharmacologists during the global pandemic. His vision is to enable the Society to realise the full potential of pharmacology, and to take the platform of UK pharmacology to a new level of therapeutic innovation. Alongside his distinguished 32-year clinical career, he brings extensive leadership experience, and a demonstrable commitment to equality and diversity in the discipline. He is already deeply involved with the Society, playing a key role in preparations for the 19th World Congress of Basic and Clinical Pharmacology 2023 to be held in Glasgow.

Sir Mark said,

I am honoured to take up this role at such an important moment for our field and for medicines and healthcare throughout the world. In the past two years, the UK has demonstrated the potential of innovative trials, undertaken at record pace with proportionate regulation, and I want to harness these progressive approaches for all our futures.

I feel privileged to have been appointed President-elect, and I intend to work tirelessly and inclusively for all pharmacologists – from our early career cohort to our most experienced fellows.

I am very much looking forward to implementing and supporting the Society’s new three-year strategy, alongside the President, my esteemed pharmacological colleague Professor Clive Page, as well as the Society’s trustees, volunteers and hard-working staff.


President Clive Page said,

I am delighted to be working with Sir Mark, and to build on his incredible experience and achievements to help guide and influence the Society’s future. This promises to be a transformational time for the Society, and Sir Mark and I are united in developing a bold and proud Society that shouts from the rooftops about its members and their impact on the world.

 


The Society’s Chief Executive Rachel Lambert-Forsyth said,

Sir Mark brings long-standing clinical experience that will be invaluable to the future of the Society, and we are excited about working with him even more closely leading up to World Congress and beyond. He has a clear mandate that both matches our strategy and will help us to deliver that strategy over the next three years.